A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 1, 2013, Pages 50-55

  Paller, C J ^a   Ye, X ^a   Wozniak, P J ^b   Gillespie, B K ^c   Sieber, P R ^d   Greengold, R H ^e   Stockton, B R ^f   Hertzman, B L ^g   Efros, M D ^h   Roper, R P ⁱ   Liker, H R ^c,j   Carducci, M A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Advanced Clinical Research Services   (United States)

^c POM Wonderful   (United States)

^d Urological Associates of Lancaster   (United States)

^e South Orange County Medical Research Center   (United States)

^f Lakeside Urology   (United States)

^g Urology Group   (United States)

^h Accumed Research Associates   (United States)

ⁱ Urology Enterprises   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

pomegranate; PSA recurrence; PSADT

Indexed keywords

PLACEBO; POLYPHENOL; POMEGRANATE EXTRACT; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ABDOMINAL PAIN; ADULT; AGED; ANGINA PECTORIS; ARTICLE; BIOLOGICAL ACTIVITY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG MEGADOSE; ESTRADIOL BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; GLEASON SCORE; HEART ARRHYTHMIA; HORMONE RESPONSE; HUMAN; HUMAN TISSUE; INTENTION TO TREAT ANALYSIS; INTESTINAL DYSMOTILITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ONCOLOGICAL PARAMETERS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN DOUBLING TIME; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SIDE EFFECT; STOMACH DISCOMFORT; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PUNICACEAE;

EID: 84873714541     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2012.20     Document Type: Article

References (27)

1. Uchio EM, Aslan M, Wells CK, Calderone J, Concato J. Impact of biochemical recurrence in prostate cancer among US veterans. Arch Intern Med 2010; 170: 1390-1395.
2. Pound CR, Christens-Barry OW, Gurganus RT, Partin AW, Walsh PC. Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. J Urol 1999; 162: 1337-1340. (Pubitemid 29428575)
3. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-439. (Pubitemid 41124175)
4. Antonarakis ES, Chen Y, Elsamanoudi SI, Brassell SA, Da Rocha MV, Eisenberger MA et al. Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. BJU Int 2010; 108: 378-385.
5. Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ et al. Prostate specific antigen working group guidelines on prostate specific antigen doubling time. J Urol 2008; 179: 2181-2185; discussion 2185-2186.
6. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004; 22: 537-556. (Pubitemid 41079783)
7. Thompson CA, Shanafelt TD, Loprinzi CL. Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist 2003; 8: 474-487. (Pubitemid 37238876)
8. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-4456. (Pubitemid 46630983)
9. Barnes S. The chemopreventive properties of soy isoflavonoids in animal models of breast cancer. Breast Cancer Res Treat 1997; 46: 169-179. (Pubitemid 28029520)
10. Faria A, Calhau C. The bioactivity of pomegranate: impact on health and disease. Crit Rev Food Sci Nutr 2011; 51: 626-634.
11. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006; 71: 1397-1421.
12. Malik A, Afaq F, Sarfaraz S, Adhami VM, Syed DN, Mukhtar H. Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci USA 2005; 102: 14813-14818. (Pubitemid 41457138)
13. Malik A, Mukhtar H. Prostate cancer prevention through pomegranate fruit. Cell Cycle 2006; 5: 371-373.
14. Albrecht M, Jiang W, Kumi-Diaka J, Lansky EP, Gommersall LM, Patel A et al. Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J Med Food 2004; 7: 274-283. (Pubitemid 39299484)
15. Koyama S, Cobb LJ, Mehta HH, Seeram NP, Heber D, Pantuck AJ et al. Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis. Growth Horm IGF Res 2010; 20: 55-62.
16. Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 2006; 12: 4018-4026. (Pubitemid 44078089)
17. Kakehi Y, Kamoto T, Shiraishi T, Ogawa O, Suzukamo Y, Fukuhara S et al. Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol 2008; 38: 122-128. (Pubitemid 351337956)
18. Chiang EC, Shen S, Kengeri SS, Xu H, Combs GF, Morris JS et al. Defining the optimal selenium dose for prostate cancer risk reduction: insights from the U-shaped relationship between selenium status, DNA damage, and apoptosis. Dose Response 2009; 8: 285-300.
19. Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat Endocrinol 2004; 3: 173-189. (Pubitemid 38724503)
20. Seeram NP, Henning SM, Zhang Y, Suchard M, Li Z, Heber D. Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr 2006; 136: 2481-2485. (Pubitemid 44521600)
21. FDA. Guidance for Industry Exposure-Response Relationships-Study Design, Data Analysis, and Regulatory Applications 2003.
22. Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E et al. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 2004; 101: 1569-1574. (Pubitemid 39318903)
23. Nelson JB, Sleep DJ, Isaacson JD, Carducci MA. Limitation of prostate-specific antigen doubling time as a predictor of outcome in hormone-naive prostate cancer. ASCO Proceedings 2006, 4566.
24. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006; 24: 2723-2728. (Pubitemid 46630568)
25. Antonarakis ES, Zahurak ML, Lin J, Keizman D, Carducci MA, Eisenberger MA. Changes in PSA kinetics predict metastasis-free survival in men with PSA-recurrent prostate cancer treated with non-hormonal agents: combined analysis of 4 phase II trials. Cancer 2011; 118: 1533-1542.
26. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003; 95: 1376-1383. (Pubitemid 37220457)
27. Beers MH, Berkow R. The Merk Manual of Diagnosis and Therapy, 17th edn. Medical Services, Internet Edition: USMEDSA, USHH 1999.